-
2022-502100-70-00
10
2021-06-23
Participants with Microsatellite Instability-High (MSI-H) or Mismatch
-
2023-505249-24-00
5
2021-05-27
HER2-positive metastatic breast cancer
-
2024-519218-30-00
5
2021-05-26
Advanced epithelial ovarian, fallopian tube or peritoneal carcinoma
-
2022-502122-41-00
5
2021-05-11
Clear cell renal cancer
-
2023-507338-26-00
5
2021-02-01
Histologically documented gastric or gastroesophageal junction adenoca
-
2023-504959-27-00
5
2020-12-09
Participants with Limited Stage-Small Cell Lung Cancer, who have recei
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2023-503591-25-00
5
2020-06-09
Non-small cell lung cancer
-
2023-505042-25-00
5
2020-05-05
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
-
2023-503500-87-00
11
2020-03-17
Muscle Invasive Bladder Cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509059-15-00
7
2019-04-30
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcino
-
2023-506921-12-00
5
2018-12-27
ER+/HER2- Breast Cancer
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
-
2023-508959-39-00
5
2025-02-20
Moderate to Severe Plaque Psoriasis
-
2023-506696-10-00
5
2024-06-18
Non-Small Cell Lung Cancer
-
2022-502457-34-00
4
2024-03-13
Triple-Negative Breast Cancer (TNBC)
-
2023-503688-41-00
5
2023-11-28
Primary Dysmenorrhea
-
2022-502716-37-00
4
2023-11-27
Recurrent or advanced/metastatic solid tumors who are immunotherapy na
-
2022-501418-69-00
5
2023-11-21
Acute Coronary Syndrome
-
2022-502023-21-00
5
2023-07-12
Prevention of pregnancy
-
2022-502024-51-00
5
2023-07-12
Prevention of pregnancy